

Indications*

In bone-adjacent soft parts of the postural and musculoskeletal system, the Dornier *AR2* can be used for the following indications:

- Epicondylopathy of the elbow
- Heel spur and plantar fasciitis
- Achillodynia
- Pain states in the shoulder (supraspinatus tendon, calcific shoulder tendinitis)
- Patella tendonitis
- Proximal iliotibial band friction syndrome
- Tibial edge syndrome
- Trochanter irritation
- Morton's neuroma
- Dupuytren's contracture
- Low back pain

Further indications in the muscular area are:

- Fibromyalgia
- Treatment of myofascial trigger points

As in the case of applications involving other medical units, the physician responsible is also accountable for selecting and monitoring the patient and for administering the shock wave therapy.

The physician conducting the treatment is obligated to make herself/himself familiar with the medical state-of-the-art for ESWT, and is to accordingly adapt the relevant application and treatment procedure.

Contraindications for Shock Wave Applications

Before applying a shock wave treatment, the attending physician must examine the relevant contraindications and make an appropriate treatment decision relative to the risks presented by alternative treatment methods.

Contraindications are, among others, as follows:

- Untreated coagulation abnormalities
- Pneumatized organs in the shock wave area
- Tumor in the focal area
- Aneurysms in the shock wave path
- (Unclear) pathological changes in the shock wave path

Relative Contraindications are:

- Shock wave exposure in the case of infections in the treatment area
- Epiphyseal cartilage in the focal area during growth
- Spinal column in the focal area
- Polyneuropathies
- Polyarthritis

The physician conducting the treatment is obligated to make herself/himself familiar with the contraindications in the latest medical publications. For pregnant patients or those with a cardiac pacemaker, it must be carefully verified if an ESWT can be conducted without any danger, based on criteria in the literature.

* The relevant national approval must be observed outside the EU.